Biocept Q2 Revenues Fall 60 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Biocept today reported a 60 percent drop in its second quarter revenues.

In a Form 10-Q filed with the US Securities and Exchange Commission, the San Diego-based company said that for the three months ended June 30, revenues fell to $19,245 from $48,369 in the year-ago quarter. The decline, it said, resulted primarily from lower sample volume related to a collaboration with the Dana-Farber Cancer Institute that is approaching completion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.